Assignee
NUVALENT INC
US·6 granted patents·8 pending applications·8 citations·filing 2021–2025
Top patents by PatentIndex Score
14 records- 0194US11542278B1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2021·Granted Jan 3, 2023·4 cites·30 claims
- 0293US11667649B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2021·Granted Jun 6, 2023·3 cites·31 claims
- 0386US12037346B2Amino-substituted heteroaryls for treating cancers with EGFR mutationsNUVALENT INC·Filed 2022·Granted Jul 16, 2024·1 cites·43 claims
- 0478US2024352037A1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2024·Application pending·0 cites
- 0574US12054498B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2022·Granted Aug 6, 2024·0 cites·48 claims
- 0673US12275742B2Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2022·Granted Apr 15, 2025·0 cites·31 claims
- 0772US2024327435A1Amino-substituted heterocycles for treating cancers with egfr mutationsNUVALENT INC·Filed 2024·Application pending·0 cites
- 0868US2025382304A1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2025·Application pending·0 cites
- 0964US2024317771A1Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compoundsNUVALENT INC·Filed 2024·Application pending·0 cites
- 1063US2025326769A1Heteroaromatic macrocyclic ether chemotherapeutic agentsNUVALENT INC·Filed 2023·Application pending·0 cites
- 1162US12043626B2Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compoundsNUVALENT INC·Filed 2022·Granted Jul 23, 2024·0 cites·36 claims
- 1260US2025339412A1Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amineNUVALENT INC·Filed 2023·Application pending·0 cites
- 1354US2024398768A1Methods of treating solid tumor using heteroaromatic macrocyclic ether compoundsNUVALENT INC·Filed 2022·Application pending·0 cites
- 1450US2023322797A1Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compoundsNUVALENT INC·Filed 2023·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →